Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report joint beneficial ownership of 3,948,910 shares of Maze Therapeutics common stock, which the statement says represents 9.02% of the outstanding common shares. The holders report shared voting and shared dispositive power over those shares and no sole voting or dispositive power.
The ownership percentage is calculated from 43,797,166 shares outstanding per the issuer's public disclosures. The filing includes a certification that the shares were not acquired to change or influence control of the issuer and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.
Maze Therapeutics reported widening operating losses as it advances clinical programs while strengthening its balance sheet through an IPO and earlier licensing deals. For the quarter ended June 30, 2025 the company recorded a net loss of $33.7 million and a six‑month loss of $66.5 million, driven by higher research and development and public‑company costs. Research and development expense rose to $28.1 million for the quarter from $19.5 million a year earlier, reflecting clinical and manufacturing progression of lead programs.
The company completed an initial public offering that generated net proceeds of approximately $127.8 million, and held $264.5 million in cash and cash equivalents as of June 30, 2025, which management says is sufficient to fund operations for at least one year. In 2024 Maze recognized $165.0 million of license revenue from three agreements, including a $150.0 million upfront from Shionogi. The balance sheet now reflects elimination of redeemable convertible preferred stock after conversion to common shares. Overall, Maze is a clinical‑stage biotech investing heavily in R&D with one year of disclosed liquidity and no product revenue from sales.
Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.